RE
VIR icon

RBC Europe’s Vir Biotechnology VIR Stock Holding History

RBC Europe’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-820
Closed -$35.7K – 1143
2021
Q3 		$35.7K Hold
820
– – ﹤0.01% 652
2021
Q2 		$38.8K Hold
820
– – ﹤0.01% 654
2021
Q1 		$42K Buy
820
+390
+91% +$21K ﹤0.01% 592
2020
Q4 		$11.5K Buy
+430
New +$14K ﹤0.01% 851

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
APF
Alaska Permanent Fund Juneau, Alaska $1.51B AUM 22.23% 1-Year Est. Return

RBC Europe's VIR Position: Q4 2021 in Review

RBC Europe sold out of Vir Biotechnology (VIR) in Q4 2021, closing a stake of 820 shares — an estimated $35.7K sold.

RBC Europe first reported a position in VIR in Q4 2020 and held it in 4 quarters. The position peaked at $42K in Q1 2021. 210 funds tracked by Wall St. Rank hold VIR as of Q4 2021.

  • RBC Europe reported no remaining Vir Biotechnology position as of Q4 2021 after selling out during the quarter.
  • RBC Europe sold 820 Vir Biotechnology shares in Q4 2021, an estimated $35.7K.
  • RBC Europe first reported a position in Vir Biotechnology in Q4 2020 and held it in 4 quarters.
  • RBC Europe's Vir Biotechnology position peaked at $42K in Q1 2021.
  • 210 funds tracked by Wall St. Rank held Vir Biotechnology as of Q4 2021.

Based on RBC Europe's 13F filing for Q4 2021, filed 14 Nov 2022.